Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 14/20 | 0.53 |
| ▸ | HTR1A | P08908 | 3/20 | 0.53 |
| ▸ | HTR7 | P34969 | 3/20 | 0.53 |
| ▸ | HTR2B | P41595 | 3/20 | 0.53 |
| ▸ | HTR1B | P28222 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.39 |
| ▸ | PRKCG | P05129 | 2/20 | 0.39 |
| ▸ | PRKCB | P05771 | 2/20 | 0.39 |
| ▸ | PRKCA | P17252 | 2/20 | 0.39 |
| ▸ | PRKACA | P17612 | 2/20 | 0.39 |
| ▸ | PRKACG | P22612 | 2/20 | 0.39 |
| ▸ | PRKACB | P22694 | 2/20 | 0.39 |
| ▸ | PRKCH | P24723 | 2/20 | 0.39 |
| ▸ | PRKCI | P41743 | 2/20 | 0.39 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.39 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.39 |
| ▸ | PRKCZ | Q05513 | 2/20 | 0.39 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.39 |
| ▸ | PRKD1 | Q15139 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6500353 | 0.94 | HTR6 (0.51) | HTR6HTR1AHTR7HTR2BHTR1B | |
| SCHEMBL6495788 | 0.88 | HTR6 (0.55) | HTR6HTR1AHTR7HTR2BHTR1B | |
| SCHEMBL6502187 | 0.83 | HTR6 (0.49) | HTR6HTR1AHTR7HTR2BHTR1B | |
| SCHEMBL6493742 | 0.83 | HTR1A (0.47) | HTR6HTR1AHTR7HTR2BHTR1B | |
| SCHEMBL6491883 | 0.83 | HTR1A (0.42) | HTR6HTR1AHTR7HTR2BHTR1B | |
| SCHEMBL6495098 | 0.81 | HTR6 (0.48) | HTR6HTR1AHTR7HTR2BPRKD3 | |
| SCHEMBL6495451 | 0.80 | HTR6 (0.55) | HTR6HTR1A | |
| SCHEMBL6496137 | 0.80 | HTR6 (0.49) | HTR6HTR1AHTR7HTR2BHTR1B | |
| SCHEMBL6500751 | 0.77 | HTR6 (0.51) | HTR6 | |
| SCHEMBL6502181 | 0.74 | HTR6 (0.44) | HTR6HTR1AHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050065186-A1 | Heterocyclyloxy-, -thioxy-and-aminobenzazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2005-03-24 | — | — | US | claimed |
| EP-1385842-A1 | HETEROCYCLYLOXY-, -THIOXY- AND -AMINOBENZAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | Wyeth (US) | 2004-02-04 | — | — | EP | claimed |
| US-20030069278-A1 | Heterocyclyloxy-, -thioxy- and -aminobenzazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2003-04-10 | — | — | US | claimed |
| WO-2002085892-A1 | HETEROCYCLYLOXY-, -THIOXY- AND -AMINOBENZAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2002-10-31 | — | — | WO | claimed |
| US-20050065186-A1 | Heterocyclyloxy-, -thioxy-and-aminobenzazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2005-03-24 | — | — | US | disclosed |
| US-6815456-B2 | ANTISEROTONINE AGENTS; CENTRAL NERVOUS SYSTEM DISORDERS | WYETH | 2004-11-09 | — | — | US | disclosed |
| EP-1385842-A1 | HETEROCYCLYLOXY-, -THIOXY- AND -AMINOBENZAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | Wyeth (US) | 2004-02-04 | — | — | EP | disclosed |
| US-20030069278-A1 | Heterocyclyloxy-, -thioxy- and -aminobenzazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2003-04-10 | — | — | US | disclosed |
| WO-2002085892-A1 | HETEROCYCLYLOXY-, -THIOXY- AND -AMINOBENZAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2002-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065186-A1 | Heterocyclyloxy-, -thioxy-and-aminobenzazole derivatives as 5-hydroxytryptamine-6 ligands | HTR6, HTR3B, HTR5A | HTR6 1/4885HTR1A 9/4885HTR7 8/4885 |
| US-20030069278-A1 | Heterocyclyloxy-, -thioxy- and -aminobenzazole derivatives as 5-hydroxytryptamine-6 ligands | HTR6, HTR3B, HTR5A | HTR6 1/4885HTR1A 8/4885HTR7 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.